NCT00652691: Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer |
|
|
| Completed | 1 | 48 | NA | filgrastim, carboplatin, cyclophosphamide, topotecan hydrochloride, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation | Mayo Clinic, National Cancer Institute (NCI) | Ovarian Cancer, Peritoneal Cavity Cancer | 06/02 | 05/16 | | |
NCT00003967: Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer |
|
|
| Completed | 1 | 24 | US | etoposide, topotecan hydrochloride | Gynecologic Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | 04/06 | | | |
NCT00005026: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer |
|
|
| Completed | 1 | | US, Canada | carboplatin, paclitaxel, topotecan hydrochloride | Gynecologic Oncology Group, National Cancer Institute (NCI) | Ovarian Cancer, Primary Peritoneal Cavity Cancer | 01/07 | | | |
NCT00002913: Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer |
|
|
| Completed | 1 | 30 | US | paclitaxel, Anzatax, Asotax, TAX, Taxol, cisplatin, CACP, CDDP, CPDD, DDP, topotecan hydrochloride, hycamptamine, Hycamtin, SKF S-104864-A, TOPO, filgrastim, G-CSF, Neupogen | National Cancer Institute (NCI) | Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer | 07/07 | | | |
